ENOV241115C60000
- 0.95
- 0.000.00%
Enovis Corp Newsroom
Enovis to Host Third Quarter 2024 Results Conference Call on November 6th
Orthopedic Implant Player Enovis' M&A Strategy Core To Growth And Competitiveness, Analyst Says
Enovis Initiated at Market Outperform by JMP Securities
JMP Securities Initiates Enovis Corp(ENOV.US) With Buy Rating, Announces Target Price $62
Enovis Is Maintained at Outperform by Evercore ISI Group
Evercore Maintains Enovis Corp(ENOV.US) With Buy Rating, Cuts Target Price to $58
Enovis (NYSE:ENOV) Is Making Moderate Use Of Debt
Express News | Enovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies
50 Stocks That May See Selling Pressure as Investors Begin Looking to Book Tax Losses
Enovis Introduces the Next Generation of Foot and Ankle Surgery Offerings at AOFAS Annual Meeting
Investors in Enovis (NYSE:ENOV) From Three Years Ago Are Still Down 47%, Even After 3.2% Gain This Past Week
Enovis Continues to Redefine Revision Knee Surgery With the Addition of EMPOWR Cones to EMPOWR Revision Knee, Creating a Comprehensive Portfolio for Efficient Revision Procedures
Enovis Introduces STAR Ankle, Now With E+ Polyethylene for Unmatched Durability
Alan Fournier's Strategic Exits and New Positions in Q2 2024: Spotlight on Enovis Corp
Enovis to Participate in Upcoming Investor Conferences
Enovis Corporation (ENOV) Fell Due to Slower Than Expected Growth
JP Morgan Maintains Neutral on Enovis, Lowers Price Target to $50
Enovis Is Maintained at Buy by Needham
Enovis Analyst Ratings
Needham Adjusts Price Target on Enovis to $65 From $82, Maintains Buy Rating